Loading
A phase 3 trial of Tamoxifen and Exemestane in advanced solid tumours, run by Tolmar Inc., active and no longer recruiting.
Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer is a phase 3 interventional study registered as NCT04906395 by Tolmar Inc., with 250 participants enrolled, started 2021-07-01 and due to reach its primary completion in 2026-04-30. Interventions recorded: TOL2506, Tamoxifen, Letrozole Tablets, Anastrozole Tablets and Exemestane Tablets.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Exemestane, Tamoxifen, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Exemestane, Tamoxifen, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Exemestane, Tamoxifen, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Exemestane, Tamoxifen, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Exemestane, Tamoxifen, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Exemestane, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Exemestane, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Tamoxifen, Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/